jivox31595@dyleris.com

It looks like you've shared an email address. How can I help you with it? Are you looking to:
  1. Sign up / register for something using this address?
  2. Report spam or phishing from this domain?
  3. Look up information about the domain dyleris.com?
  4. Something else entirely?
Let me know what you need!

Make me a detailed ppt on a case presentation of peripheral vascular disease for my pg general surgery presentation from standard surgery practical and theory books covering all the viva questions

Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready! Download it here:

PVD Case Presentation PG Surgery

Presentation · PPTX


What's Inside (18 Slides)

The deck uses a deep navy + arterial red + gold palette designed for a surgical case presentation. Here's the full breakdown:
SlideContent
1Title Slide — with all source books listed
2Case Vignette — 58M, diabetic, smoker, claudication + rest pain + ulcer + gangrene (covers all 4 Fontaine stages in one case)
3Definitions & Classification — Fontaine I–IV table with ABI values + TASC II overview
4Aetiology & Risk Factors — all causes of PVD + risk factor table (modifiable/non-modifiable)
5Pathophysiology — atherosclerosis step-by-step flow + haemodynamic & tissue consequences
6Clinical Features / Symptoms — Fontaine-correlated symptom table + Leriche syndrome
7Clinical Examination — Inspection / Palpation / Special Tests (Buerger's, Adson's, Allen's)
8Buerger's Test + Buerger's Disease — both in one slide; Buerger's angle interpretation
9Investigations — ABI interpretation table + Duplex, CTA, MRA, DSA, TBI, bloods
10Acute Limb Ischaemia — 6 Ps + Embolism vs. Thrombosis comparison + Rutherford ALI
11Medical & Endovascular Management — risk modification + antiplatelet + PTA + stenting + thrombolysis
12Surgical Management — bypass procedures table + amputation levels + sympathectomy
13Gangrene — Dry vs. Wet vs. Gas gangrene + Arterial vs. Venous vs. Neuropathic ulcer
14Raynaud's Phenomenon + TOS / Cervical Rib — triphasic colour change + Adson's test
15–16Viva Q&A (16 questions) — all classic PG surgery viva topics answered concisely
17Summary / Key Take-home Points
18References — Bailey & Love, S. Das, Schwartz, Sabiston, Current Surgical Therapy, TASC II
attachment

Detailed answers according to the weightage from standard textbooks

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
All five questions answered in full. Here is a brief guide to what each answer covers:

Quick Navigation

QDiagnosis/TopicKey Points Covered
Q1 (20M)Carcinoma StomachArterial supply (named vessels), lymph node stations N1–N16, D1/D2 dissection, transcoelomic spread; Aetiology (H. pylori/Correa cascade, dietary, genetic), Borrmann + Laurén classification, EGC vs. advanced, TNM staging 8th ed.; Surgery (subtotal/total gastrectomy, D2), FLOT chemotherapy, Trastuzumab, Palliative options
Q2 (20M)Congenital Kidney Anomalies + PUJOComplete CAKUT classification (agenesis, ectopia, horseshoe, ADPKD, MCDK, duplex, retrocaval ureter); PUJO intrinsic/extrinsic causes, Dietl's crisis, DTPA renogram (DRF <40%, T½ >20 min), Anderson-Hynes pyeloplasty, HoLEP endopyelotomy, laparoscopic/robotic repair
Q3 (20M)Penetrating Abdominal TraumaMLC documentation checklist (entry/exit wound description, police intimation, chain of evidence); ATLS primary survey; Stab vs. GSW; FAST, CT, DPL, DL; Damage control surgery (lethal triad); Organ-specific management
Q4a (10M)Post-LSCS DVTVirchow's triad in pregnancy, hypercoagulable state, clinical features (Homan's, Moses', phlegmasia); Wells score; Duplex USS; LMWH (Enoxaparin), duration, prevention
Q4b (10M)Chronic Pancreatitis + SteatorrhoeaTIGAR-O aetiology, alcohol mechanism, exocrine insufficiency (90% loss), faecal elastase, MRCP "chain of lakes"; PERT (Creon), alcohol cessation, Lateral PJ (Puestow/Frey), Beger procedure, Whipple's
Q5a (10M)Recent Advances Ventral HerniaBiological/biosynthetic/anti-adhesion meshes, laparoscopic IPOM Plus, robotic rTAPP/eTEP, TAR (posterior CST), botulinum toxin, ERAS, Rives-Stoppa
Q5b (10M)LASER in Uro-Ano-RectalHoLEP, Greenlight (PVP), ThuVEP for BPH; Ho:YAG lithotripsy, TFL for stones; HeLP/LHP for haemorrhoids; FiLaC for fistula-in-ano; SiLaC for pilonidal sinus; CO₂ for anal warts

Smoking index

Finding Sources
Finding Sources
Finding Sources

Smoking Index

Definition and Formula

Smoking Index (SI) = Number of cigarettes smoked per day × Number of years of smoking
This is the standard formula used in Indian clinical practice and surgical/pulmonology examinations.
Example: A patient who smokes 20 cigarettes/day for 15 years has an SI = 20 × 15 = 300

Clinical Significance / Cut-offs

Smoking IndexInterpretation
< 100Low risk
100 – 299Moderate risk — monitor
≥ 300Significant risk — COPD, chronic bronchitis, peripheral vascular disease
≥ 400High risk for lung carcinoma

Pack-Year Index (International Equivalent)

The term used in Western/international textbooks is the Pack-Year:
Pack-Years = (Cigarettes smoked per day ÷ 20) × Number of years smoked
Since 1 pack = 20 cigarettes, a person smoking 20 cigs/day for 10 years = 10 pack-years.
Pack-YearsClinical Relevance
≥ 10 pack-yearsThreshold for HPV+ head & neck cancer risk stratification
≥ 20 pack-yearsLung cancer screening eligibility (USPSTF / NLST criteria)
> 30 pack-yearsStrong COPD risk (Robbins Pathology)
> 40 pack-yearsVery high COPD / lung malignancy risk
Conversion: SI of 300 ≈ 15 pack-years; SI of 400 ≈ 20 pack-years.

Uses of Smoking Index in Clinical Practice

  1. COPD risk assessment — SI ≥300 = clinically significant smoking history; correlates with spirometric obstruction
  2. Lung cancer screening — USPSTF recommends annual low-dose CT (LDCT) for patients aged 50–80 with ≥20 pack-years who currently smoke or quit within 15 years
  3. Surgical risk stratification — pre-operative pulmonary risk; smoking cessation advised ≥8 weeks before elective surgery
  4. Head & neck oncology — ≤10 vs. >10 pack-years distinguishes low/high-risk groups in HPV+ oropharyngeal carcinoma (Schwartz 11e)
  5. Buerger's disease — heavy smoking (high SI) in young males is the single most important diagnostic criterion
  6. Cardiovascular risk — every 10 pack-year increment increases MI/stroke risk
  7. Lung donor assessment — smoking history <20 pack-years is a standard donor criterion (Bailey & Love 28e)

Heaviness of Smoking Index (HSI)

A separate validated questionnaire tool measuring nicotine dependence (not the same as SI):
  • Based on 2 parameters: cigarettes per day and time to first cigarette after waking
  • Score 0–6; higher score = greater nicotine dependence
  • Used to guide cessation therapy (NRT dosing, varenicline)
(Fuster & Hurst's The Heart, 15e)

Bottom line for exams: Smoking Index = cigs/day × years smoked. SI ≥300 = significant risk for COPD/PVD; SI ≥400 = significant risk for lung cancer. International equivalent is Pack-Years (divide SI by 20).

Hyperasthesia in peripheral arterial disease

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources

Hyperaesthesia in Peripheral Arterial Disease

The Textbook Statement (S. Das, Manual of Clinical Surgery, 13e)

"Sensation of the gangrenous area is often lost. The patient is unable to move the part when the viability of the deeper tissues becomes at stake. On the border line of the gangrene the skin becomes hyperaesthetic." — S. Das, Chapter 6: Peripheral Vascular Disease, p. 92

What is Hyperaesthesia Here?

Hyperaesthesia = abnormally increased sensitivity of the skin to stimuli (touch, pinprick, temperature) — the opposite of anaesthesia/hypoaesthesia.
In the context of peripheral arterial disease and gangrene, it is a neurological sign found specifically at the demarcation zone between ischaemic/dead tissue and viable tissue.

Pathophysiology — Why Does Hyperaesthesia Occur at the Border?

Understanding this requires knowing how ischaemia affects peripheral nerves in a spatial and temporal gradient:

Zone 1 — Gangrenous Core (Central ischaemic area)

  • Complete ischaemia → anaesthesia (total loss of sensation)
  • Peripheral nerves are exquisitely sensitive to ischaemia — among the first tissues to lose function
  • C-fibres (pain) and A-delta fibres (temperature/sharp pain) die earliest
  • Motor function also lost — patient cannot move the gangrenous part
  • Skin: black, mummified (dry gangrene) or necrotic (wet)

Zone 2 — Border Zone / Demarcation Line (Transitional area)

  • Partial ischaemia — blood supply is just enough to keep nerves alive but not enough for normal function
  • Relative ischaemia + inflammatory mediators released from necrotic tissue (prostaglandins, bradykinin, histamine, substance P, TNF-α) sensitise peripheral nociceptors
  • C-fibres become sensitised (peripheral sensitisation) → lowered threshold to stimulation → hyperaesthesia
  • This is analogous to the tender, hyperaesthetic skin around any area of local inflammation/tissue injury
  • The demarcation line is also the zone of reactive inflammation — vasodilatation, oedema, immune cell infiltration

Zone 3 — Viable Proximal Tissue

  • Normal or near-normal sensation
  • May show trophic changes (hair loss, shiny skin) if chronic ischaemia is present

Clinical Significance

FeatureSignificance
Hyperaesthesia at borderMarks the demarcation line — helps define extent of gangrene
Anaesthesia of coreConfirms non-viability of gangrenous tissue
Useful for amputation planningAmputate at or proximal to the zone of normal sensation to ensure tissue viability
Distinguishes dry from early wet gangreneWet gangrene may show broader zone of hyperaesthesia due to spreading infection and inflammation
Prognostic value in acute limb ischaemiaPresence of paraesthesia/anaesthesia = severe ischaemia (Rutherford IIb/III); neurological deficit → irreversible ischaemia impending

Spectrum of Sensory Changes in PAD (Summary)

Proximal viable tissue          Border zone            Gangrenous core
       ↓                             ↓                        ↓
Normal sensation          HYPERAESTHESIA              ANAESTHESIA
                      (sensitised nociceptors,       (nerves dead /
                       inflammatory mediators)         non-functional)

Related Neurological Examination Points in PAD (S. Das 13e)

  • Sensation: Test with pin-prick and light touch across the ischaemic limb — maps zones of sensory loss
  • Motor function: Patient is unable to move the gangrenous part when deeper tissues are non-viable — motor nerves equally ischaemia-sensitive
  • Neurological deficit in Acute Limb Ischaemia (ALI): Paraesthesia → anaesthesia → paralysis = sequential, worsening ischaemia; paralysis = surgical emergency (irreversible within 4–6 hours)
  • Central nervous system causes of sensory loss must be excluded in superficial ulceration: hemiplegia, transverse myelitis, syringomyelia, tabes dorsalis (S. Das 13e)

Exam-Ready Summary

Hyperaesthesia in PAD is the increased skin sensitivity found at the border line of gangrene in peripheral arterial disease. It is caused by sensitisation of peripheral nociceptors by ischaemia-induced inflammatory mediators at the demarcation zone. Central to this zone is anaesthesia (dead nerves), and proximal to it is normal sensation. Clinically, it helps define the extent of gangrene, guides the level of amputation, and indicates that the tissue at the border is still viable but severely stressed. (S. Das, Manual of Clinical Surgery 13e, p. 92)
This is a shared conversation. Sign in to Orris to start your own chat.